• Global nutrition company ADM has received approval from the Therapeutic Goods Administration, part of the Australian Department of Health, for its spore-forming probiotic DE111 (Bacillus subtilis).
Source: Getty Images
    Global nutrition company ADM has received approval from the Therapeutic Goods Administration, part of the Australian Department of Health, for its spore-forming probiotic DE111 (Bacillus subtilis). Source: Getty Images
Close×

Global nutrition company ADM has received approval from the Therapeutic Goods Administration (TGA) for its spore-forming probiotic DE111 (Bacillus subtilis).

Clinical results have shown that DE111 supports digestive health and immune function, can survive through the stomach and germinate in the small intestine, and supports a healthy gastrointestinal tract, gut functions and microbiome diversity.

The gut health supporting probiotic was also recently approved by China’s National Health Commission (NHC), allowing ADM to expand the availability of DE111 to new markets. The company states that local regulations must still be reviewed to confirm permissibility of ingredients for each food category.

ADM president of health & wellness APAC, Helen Hu, said this was an important milestone for the company, as DE111 is the first Bacillus subtilis strain to be approved by the TGA in Australia.

“By expanding access to DE111, we’re facilitating new innovation possibilities for our Australian customers, enabling the development of pioneering gut health-supporting products.

“Additionally, the continued approval of DE111 by important government authorities demonstrates its high quality, safety and alignment with strict regulatory standards,” Hu said.

With 81 per cent of Australian consumers recognising a link between digestive health and overall well-being, and 76 per cent seeing a connection between digestive health and immune function, it is clear that gut health products are a rising market.

The Australian probiotic supplement market is anticipated to grow, with Euromonitor reporting a forecasted CAGR of 2.7 per cent between 2023 and 2028.

“DE111 is a spore-forming probiotic, which means it can withstand harsh formulation environments that may otherwise damage conventional probiotics,” Hu said.

“This robustness is paving the way for new, convenient and enjoyable foods, beverages and dietary supplements that meet people where they are on their wellness journeys, especially as more consumers make the connection between their gut and digestive health and other aspects of well-being.”

Packaging News

Ego Pharmaceuticals has unveiled a bold new chapter in its commitment to local manufacturing, announcing a $156 million, decade-long investment to expand its Victorian operations.

After an extended period of grace for brands whose packaging carried the REDcycle and Return to Store labelling, the deadline is here for complete removal from soft plastic packaging in Australia.

The 2025 PKN Women in Packaging Awards, presented in Sydney today, have once again shone a powerful spotlight on the exceptional women driving progress, innovation, and impact across every corner of the packaging value chain.